Treatment options for second-stage gambiense human African trypanosomiasis

References

• Burri C, Chappuis F, Brun R. Human African trypanosomiasis. In: Farrar J, Hotez PJ, Junghanss T, Gagandeep K, Lalloo D, White NJ, editors. Manson’s Tropical Diseases (23). W.B. Saunders Ltd; London, UK: 2014. p. 606-21
   Google Scholar
• World Health Organization. Working to overcome the global impact of neglected diseases: first WHO report on neglected tropical diseases. WHO; Geneva, Switzerland: 2010. p. 82-90
   Google Scholar
• Simarro PP, Diarra A, Ruiz Postigo JA, et al. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis 2011;5(2):e1007
   PubMed Web of Science ®Google Scholar
• Pepin J, Meda HA. The epidemiology and control of human African trypanosomiasis. Adv Parasitol 2001;49:71-132
   PubMed Web of Science ®Google Scholar
• World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases. Second WHO report on neglected tropical diseases. WHO; Geneva, Switzerland: 2013. p. 60-6
   Google Scholar
• Tong J, Valverde O, Mahoudeau C, et al. Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo. Confl Health 2011;5:7
   PubMedGoogle Scholar
• Chappuis F, Loutan L, Simarro P, et al. Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 2005;18(1):133-46
   PubMed Web of Science ®Google Scholar
• World Health Organization. Control and surveillance of human African trypanosomiasis. WHO Technical Report Series. (984). WHO; Geneva, Switzerland: 2013
   Google Scholar
• Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006;97(1):55-64
   PubMed Web of Science ®Google Scholar
• Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978;58(3):169-76
   PubMedGoogle Scholar
• Jamonneau V, Ilboudo H, Kabore J, et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 2012;6(6):e1691
   PubMed Web of Science ®Google Scholar
• Ollivier G, Legros D. Human African trypanosomiasis: a history of its therapies and their failures. Trop Med Int Health 2001;6(11):855-63
   PubMedGoogle Scholar
• Friedheim EA. Mel B in the treatment of tryparsamide resistant T. gambiense sleeping sickness: observations on drug resistance in the trypanosomes of the French Cameroun. Am J Trop Med Hyg 1951;31(2):218-35
   PubMedGoogle Scholar
• Pepin J, Mpia B. Trypanosomiasis relapse after melarsoprol therapy. Democratic Republic of Congo, 1982-2001. Emerg Infect Dis 2005;11(6):921-7
   PubMedGoogle Scholar
• Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994;33:1-47
   PubMed Web of Science ®Google Scholar
• Fairlamb AH, Carter NS, Cunningham M, Smith K. Characterisation of melarsen-resistant Trypanosoma brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol 1992;53(1-2):213-22
   PubMed Web of Science ®Google Scholar
• Pepin J, Mpia B. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Trans R Soc Trop Med Hyg 2006;100(5):437-41
   PubMedGoogle Scholar
• Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-Day melarsoprol schedule for the treatment of late-stage human african trypanosomiasis: confirmation from a Multinational Study (Impamel II). J Infect Dis 2005;191(11):1922-31
   PubMedGoogle Scholar
• Burri C, Nkunku S, Merolle A, et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000;355(9213):1419-25
   PubMed Web of Science ®Google Scholar
• Legros D, Evans S, Maiso F, et al. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999;93(4):439-42
   PubMed Web of Science ®Google Scholar
• Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 2001;6(5):330-4
   PubMedGoogle Scholar
• Balasegaram M, Harris S, Checchi F, et al. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bull World Health Organ 2006;84(10):783-91
   PubMed Web of Science ®Google Scholar
• Bisser S, N’Siesi FX, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007;195(3):322-9
   PubMed Web of Science ®Google Scholar
• Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001;6(5):390-400
   PubMed Web of Science ®Google Scholar
• Eperon G, Schmid C, Loutan L, Chappuis F. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children. Acta Trop 2007;101(1):31-9
   PubMedGoogle Scholar
• Seixas J. Investigations on the encephalopathic syndrome during melarsoprol treatment of human African trypanosomiasis. Instituo de Higiene e medicina tropical. 2004
   Google Scholar
• Van Nieuwenhove S, Schechter PJ, Declercq J, et al. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg 1985;79(5):692-8
   PubMedGoogle Scholar
• Bacchi CJ, Nathan HC, Hutner SH, et al. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 1980;210(4467):332-4
   PubMed Web of Science ®Google Scholar
• Iten M, Mett H, Evans A, et al. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chemother 1997;41(9):1922-5
   PubMedGoogle Scholar
• Bacchi CJ, Garofalo J, Ciminelli M, et al. Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. Biochem Pharmacol 1993;46(3):471-81
   PubMedGoogle Scholar
• Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008;336(7646):705-8
   PubMed Web of Science ®Google Scholar
• Milord F, Pepin J, Loko L, et al. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 1992;340(8820):652-5
   PubMedGoogle Scholar
• Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005;41(5):748-51
   PubMed Web of Science ®Google Scholar
• Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009;374(9683):56-64
   PubMed Web of Science ®Google Scholar
• Pepin J, Khonde N, Maiso F, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 2000;78(11):1284-95
   PubMedGoogle Scholar
• Burri C, Brun R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 2003;90(Supp 1):S49-52
   PubMed Web of Science ®Google Scholar
• Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 2011;286(15):13088-95
   PubMed Web of Science ®Google Scholar
• Janssens PG, De Muynck A. Clinical trials with “nifurtimox” in African trypanosomiasis. Ann Soc Belg Med Trop 1977;57(4-5):475-80
   PubMedGoogle Scholar
• Moens F, De Wilde M, Ngato K. Clinical trial of nifurtimox in human African trypanosomiasis. Ann Soc Belg Med Trop 1984;64(1):37-43
   PubMedGoogle Scholar
• Pepin J, Milord F, Mpia B, et al. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 1989;83(4):514-17
   PubMedGoogle Scholar
• Pepin J, Milord F, Meurice F, et al. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 1992;86(3):254-6
   PubMedGoogle Scholar
• Van Nieuwenhove S, Declercq J. Nifurtimox (lampit) treatment in late stage of gambiense sleeping sickness. Presented at 17th meeting of International Scientific Council for Trypanosomiasis Research and control; Arusha, Tanzania; 1981. p. 206-8
   Google Scholar
• Van Nieuwenhove S. Gambiense sleeping sickness: re-emerging and soon untreatable? Bull World Health Organ 2000;78(11):1283
   PubMedGoogle Scholar
• Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 2006;1(8):e39
   Google Scholar
• Checchi F, Piola P, Ayikoru H, et al. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 2007;1(2):e64
   Google Scholar
• Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 2007;152(8):1155-71
   PubMed Web of Science ®Google Scholar
• Priotto G, Kasparian S, Ngouama D, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007;45(11):1435-42
   PubMed Web of Science ®Google Scholar
• Franco JR, Simarro P, Diarra A, et al. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med 2012;3:1-9
   PubMedGoogle Scholar
• Schmid C, Kuemmerle A, Blum J, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis 2012;6(11):e1920
   Google Scholar
• Alirol E, Schrumpf D, Amici Heradi J, et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: medecins Sans Frontieres experience in the Democratic Republic of the Congo. Clin Infect Dis 2013;56(2):195-203
   PubMed Web of Science ®Google Scholar
• Yun O, Priotto G, Tong J, et al. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 2010;4(5):e720
   PubMed Web of Science ®Google Scholar
• Coyne PE Jr. The eflornithine story. J Am Acad Dermatol 2001;45(5):784-6
   PubMedGoogle Scholar
• Simarro PP, Franco J, Diarra A, et al. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 2012;139(7):842-6
   PubMedGoogle Scholar
• Moran M, Strub-Wourgaft N, Guzman J, et al. Registering new drugs for low-income countries: the African challenge. PLoS Med 2011;8(2):e1000411
   Google Scholar
• Torreele E, Bourdin Trunz B, Tweats D, et al. Fexinidazole–a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 2010;4(12):e923
   PubMed Web of Science ®Google Scholar
• Tarral A, Blesson S, Mordt OV, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet 2014;53(6):565-80
   PubMed Web of Science ®Google Scholar
• Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 2011;5(6):e1151
   PubMed Web of Science ®Google Scholar
• Trunz BB, Jedrysiak R, Tweats D, et al. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis. Eur J Med Chem 2011;46(5):1524-35
   PubMedGoogle Scholar
• Frearson JA, Brand S, McElroy SP, et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 2010;464(7289):728-32
   PubMed Web of Science ®Google Scholar
• Brand S, Cleghorn LA, McElroy SP, et al. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem 2012;55(1):140-52
   PubMedGoogle Scholar
• Wenzler T, Yang S, Braissant O, et al. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis. Antimicrob Agents Chemother 2013;57(11):5330-43
   PubMedGoogle Scholar
• Wenzler T, Yang S, Patrick DA, et al. In vitro and in vivo evaluation of 28dap010, a novel diamidine for treatment of second-stage African sleeping sickness. Antimicrob Agents Chemother 2014;58(8):4452-63
   PubMedGoogle Scholar
• GlaxoSmithKline. Partnerships: neglected tropical diseases. Available from: www.gsk.com/partnerships/neglected-tropical-diseases.html
   Google Scholar
• Novartis. Novartis Institute for Tropical Diseases (NITD). Available from: www.nibr.com/research/developing_world/NITD/index.shtml
   Google Scholar
• Büscher P, Gilleman Q, Lejon V. Rapid diagnostic test for sleeping sickness. N Engl J Med 2013;368(11):1069-70
   PubMedGoogle Scholar
• Büscher P, Mertens P, Leclipteux T, et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health 2014;2(6):e359-63. Published online May 9, 2014 Available from: http://dx.doi.org/10.1016/S2214-109X(14)70203-7
   Google Scholar
• Robays J, Lefevre P, Lutumba P, et al. Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health 2007;12(2):290-8
   PubMedGoogle Scholar
• Palmer JJ, Surur EI, Goch GW, et al. Syndromic algorithms for detection of gambiense human African trypanosomiasis in South Sudan. PLoS Negl Trop Dis 2013;7(1):e2003
   Google Scholar
• World Health Organization. Stakeholders call on WHO to lead a network aimed at elimination of human African trypanosomiasis (2014). Available from: www.who.int/trypanosomiasis_african/meeting_declaration_2014_intro/en/
   Google Scholar
• Target product profile of new treatments for human African trypanosomiasis. Available from: www.dndi.org/diseases-projects/diseases/hat/target-product-profile.html
   Google Scholar